Last updated: August 8, 2026
Cidofovir is a mature antiviral with limited commercial value, weak current exclusivity protection, and persistent clinical relevance in narrow indications. Gilead Sciences commercialized cidofovir as Vistide for cytomegalovirus retinitis in patients with AIDS. The product’s principal commercial barriers are nephrotoxicity, intravenous administration, mandatory probenecid coadministration, and competition from safer oral or targeted antivirals.
Cidofovir has no meaningful remaining patent moat in the United States. Its commercial market is driven by hospital use, specialty pharmacy access, compounding, and off-label treatment of resistant DNA-virus infections rather than broad outpatient demand. Public company filings do not provide a current standalone revenue series for Vistide, indicating that sales are immaterial relative to Gilead’s major HIV, hepatitis, and oncology products.
What is cidofovir and how is it used?
Cidofovir is an acyclic nucleotide phosphonate antiviral. It inhibits viral DNA polymerase after intracellular conversion to its active diphosphate form. The drug has activity against cytomegalovirus, adenovirus, herpesviruses, human papillomavirus, and other DNA viruses.
The FDA approved Vistide in 1996 for the treatment of cytomegalovirus retinitis in adults with AIDS and without clinically significant renal dysfunction. The approved regimen requires intravenous infusion and oral probenecid, together with intensive hydration and renal monitoring. The label includes a boxed warning for nephrotoxicity and other serious risks, including neutropenia, ocular toxicity, and potential carcinogenicity or reproductive toxicity concerns. [1]
Current clinical use is concentrated in situations where standard therapies are ineffective, unavailable, or contraindicated. These uses include:
- Resistant or refractory cytomegalovirus infection.
- Adenovirus infection in immunocompromised patients.
- Severe human papillomavirus disease in selected specialist settings.
- Other refractory DNA-virus infections under institutional protocols.
For many off-label uses, evidence comes from retrospective studies, case series, and specialist experience rather than large randomized trials.
When does cidofovir lose exclusivity?
Cidofovir lost meaningful U.S. market exclusivity many years ago. The principal historical patent estate was based on Gilead’s acyclic phosphonate antiviral chemistry.
| Exclusivity or IP item |
Status |
| U.S. FDA approval |
June 26, 1996 |
| Orphan-drug exclusivity |
Historically expired in 2003 |
| Principal early U.S. compound patent |
U.S. Patent No. 5,142,051 |
| Approximate original patent expiry |
2010, based on the pre-Uruguay Round patent term |
| Current composition-of-matter protection |
Expired |
| Current U.S. generic-barrier significance |
Low |
| Biosimilar exclusivity |
Not applicable |
The principal compound patent was filed before the 1995 change to a 20-year term from the earliest effective nonprovisional filing date. Its term therefore followed the older 17-year period from issuance, subject to any applicable adjustments. The patent’s commercial protection expired approximately a decade and a half ago. [2]
The orphan designation created seven years of marketing exclusivity, but that period expired in 2003. Orphan exclusivity did not prevent later development of products with different active ingredients, different indications, or different formulations.
What is the Orange Book status of cidofovir?
Vistide was an FDA-approved branded product, and its historical regulatory protection was linked to the approved injection and indication. The relevant regulatory issue today is commercial listing and availability rather than surviving patent protection.
Cidofovir is a small-molecule drug, so it does not receive biosimilar treatment under the Public Health Service Act. A competing product would follow the abbreviated new drug application pathway if an eligible reference product and commercial market existed. FDA approval of a generic cidofovir injection would generally require demonstration of pharmaceutical equivalence and bioequivalence or an appropriate waiver or alternative approach.
The practical market constraint is demand. A generic manufacturer must support sterile injectable production, renal-risk labeling, quality systems, and a small volume of demand. These factors can discourage entry even after patent expiry.
Historical Orange Book information should be distinguished from current commercial availability. A product may retain an FDA approval history while having limited distribution, intermittent supply, or no active branded marketing. Gilead’s public filings do not identify Vistide as a major separately reported revenue product. [3]
How large is the cidofovir market?
The cidofovir market is small compared with markets for valganciclovir, letermovir, acyclovir, or newer targeted anti-infectives. No reliable public source provides a current global market size that isolates cidofovir sales across branded, generic, compounded, and off-label channels.
Market demand has several defining characteristics:
| Market driver |
Effect on cidofovir demand |
| CMV retinitis |
Historical core indication, reduced by effective HIV therapy |
| Resistant CMV |
Supports specialist and salvage use |
| Adenovirus |
Creates hospital demand in transplant and immunocompromised care |
| HPV and other off-label use |
Generates limited but geographically dispersed demand |
| IV administration |
Restricts outpatient convenience |
| Nephrotoxicity |
Shifts use toward alternatives |
| Probenecid and hydration requirements |
Increases administration burden |
| Generic competition |
Can reduce price but may not expand total volume |
| Compounding |
May fill supply gaps but raises quality and consistency concerns |
The largest structural reduction in the original market came from the decline of AIDS-related CMV retinitis after combination antiretroviral therapy became standard. Valganciclovir and ganciclovir also offer more established CMV treatment pathways, while letermovir has reduced the need for some CMV prophylaxis use in hematopoietic stem-cell transplant patients.
What is cidofovir’s financial trajectory?
Cidofovir’s financial trajectory is mature-to-declining, with low strategic importance to Gilead’s consolidated results. The product had commercial value in the late 1990s and early 2000s when CMV retinitis represented a larger treatment market. Its contribution declined as HIV mortality and opportunistic infections fell and oral or better-tolerated alternatives became more widely used.
Gilead’s annual reports generally aggregate smaller products into broader revenue categories rather than disclose Vistide sales as a standalone line item. This prevents a defensible current revenue estimate based solely on public company reporting. [3]
The financial profile can be summarized as follows:
- Original value came from orphan pricing and limited competition.
- Volume declined as CMV retinitis became less common.
- Patent expiry removed the ability to sustain premium pricing through exclusivity.
- Remaining demand shifted toward low-volume, high-acuity hospital and specialist use.
- Manufacturing and distribution economics became more important than patent protection.
- Strategic value persists mainly as an option for difficult-to-treat DNA-virus infections.
Cidofovir is unlikely to become a material growth product without a new formulation, a validated indication, or a major infectious-disease event that increases demand for broad-spectrum DNA-virus therapy.
What formulations are protected by cidofovir patents?
The original commercial product is an intravenous cidofovir formulation. Its practical limitations are central to the commercial analysis:
- Intravenous administration.
- Required hydration.
- Probenecid coadministration.
- Renal monitoring.
- Dose modification or discontinuation based on renal function.
Patent protection for the original cidofovir active ingredient and basic product concept has expired. Later formulation or delivery patents could theoretically protect improvements such as topical, intravitreal, oral, lipid-conjugated, nanoparticle, or depot formulations. Such protection would apply only to the specifically claimed formulation or use and would not restore composition-of-matter exclusivity for conventional intravenous cidofovir.
A reformulated product would also face development risks. Systemic nephrotoxicity, local tolerability, tissue distribution, and the need to demonstrate meaningful clinical benefit would determine commercial viability. A topical or localized formulation could create a differentiated product, but it would require new clinical and regulatory support.
What method-of-use patents and regulatory exclusivity remain?
The original FDA approval was for CMV retinitis in adults with AIDS. That indication-specific exclusivity has expired. Later use of cidofovir for adenovirus, resistant CMV, HPV, or other infections is generally off-label unless separately supported by a new FDA approval.
A new sponsor could seek patents on:
- Treatment of a defined resistant-virus population.
- A dosing schedule that reduces renal toxicity.
- Combination use with probenecid or another protective agent.
- Local administration to a specific tissue.
- A selected immunocompromised population.
- A formulation that improves tissue exposure or reduces systemic exposure.
Such patents would protect only the claimed method or formulation. They would not prevent all use of unpatented cidofovir.
There is no current biosimilar risk because cidofovir is not a biologic. The principal competitive threat is generic or compounded small-molecule supply, not biosimilar substitution.
Which companies are challenging cidofovir?
No major current Paragraph IV challenge is central to the cidofovir market. The relevant patents expired long ago, reducing the commercial rationale for high-profile patent litigation.
The competitive landscape instead includes:
| Competitor |
Role relative to cidofovir |
| Ganciclovir |
Established CMV treatment, usually preferred where appropriate |
| Valganciclovir |
Oral prodrug with broader outpatient utility |
| Foscarnet |
Alternative for resistant CMV and herpesvirus infections; also nephrotoxic |
| Letermovir |
CMV prophylaxis in defined transplant settings, not a direct treatment substitute in all uses |
| Brincidofovir |
Distinct lipid-conjugated antiviral; approved for smallpox, not a generic cidofovir equivalent |
| Compounded cidofovir |
Can support off-label and local-use demand |
| Investigational antivirals |
Potential future alternatives for resistant CMV or adenovirus |
Foscarnet is the closest clinical alternative in some resistant-virus settings, but it also has substantial renal and electrolyte toxicity. Valganciclovir is a stronger competitor for conventional CMV management because it is orally administered.
What patent litigation and settlement risks affect cidofovir?
Cidofovir has low current litigation risk. The main patent estate is expired, and there is no evident commercial settlement structure comparable to those surrounding high-revenue oncology, immunology, or diabetes products.
Potential disputes would more likely concern:
- Generic product quality or supply.
- Compounding practices.
- Trade secrets involving manufacturing.
- New formulation patents.
- Labeling or method-of-use claims.
- Product liability and renal-toxicity disclosures.
A Paragraph IV filing against expired compound patents would not create a meaningful barrier to entry. Any future litigation would probably center on a newly patented formulation, a restricted indication, or manufacturing know-how rather than the cidofovir molecule itself.
How strong is the cidofovir patent estate?
The legacy estate is weak from an exclusivity perspective but may remain relevant as technical prior art.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Orphan exclusivity |
Expired |
| Product-specific commercial moat |
Low |
| Formulation protection |
Limited unless separately patented |
| Method-of-use protection |
Limited and claim-specific |
| Manufacturing complexity |
Moderate for sterile injectable production |
| Regulatory barrier |
Moderate because of safety and quality requirements |
| Generic entry barrier |
Economic and operational rather than legal |
| Biosimilar exposure |
None |
The manufacturing process is not trivial. Cidofovir injection requires sterile production, validated controls, stability data, and appropriate handling of a drug with significant renal toxicity. These requirements can limit the number of suppliers even where patents do not.
What generic launch scenarios exist for cidofovir?
Three scenarios are commercially plausible.
Generic intravenous launch
A generic injectable could enter at a lower price, but total market expansion would likely be limited. Hospitals and specialists would gain a lower-cost source, while the product would remain restricted by toxicity and administration burden.
Shortage-driven or compounding supply
Compounded cidofovir may become more relevant when branded or generic supply is inconsistent. This channel can support niche demand but may face variability in availability, institutional approval, and quality controls.
Reformulated or indication-specific product
A sponsor could pursue a new formulation or localized delivery system. This is the only scenario with a credible path to material value creation, but it would require clinical differentiation and new intellectual property. A simple relaunch of conventional IV cidofovir would have limited upside.
How does cidofovir compare with competing CMV drugs?
| Attribute |
Cidofovir |
Valganciclovir |
Foscarnet |
Letermovir |
| Administration |
IV |
Oral or IV through ganciclovir pathway |
IV |
Oral or IV |
| Main role |
Salvage and selected CMV use |
Standard CMV treatment |
Resistant CMV and herpesviruses |
CMV prophylaxis |
| Renal toxicity |
High |
Clinically important |
High |
Lower renal toxicity profile |
| Blood toxicity |
Less prominent than ganciclovir but possible |
Significant neutropenia risk |
Electrolyte toxicity |
More limited |
| Generic exposure |
High |
High |
High |
Lower, depending on jurisdiction |
| Commercial scale |
Small |
Larger |
Niche |
Commercially meaningful prophylaxis market |
| Patent strength |
Expired |
Largely mature |
Mature |
Newer and stronger historically |
Cidofovir’s differentiation is broad DNA-virus activity and utility when other therapies fail. Its weakness is the treatment burden and safety profile.
Key Takeaways
- Cidofovir is a mature, low-revenue antiviral with limited but persistent specialist demand.
- Vistide’s principal compound patent and orphan exclusivity expired years ago.
- No biosimilar pathway applies because cidofovir is a small molecule.
- Current competition comes from valganciclovir, ganciclovir, foscarnet, letermovir, and compounded supply.
- The original CMV retinitis market contracted after effective HIV therapy reduced opportunistic infections.
- Public filings do not disclose current standalone Vistide revenue, so precise revenue estimates are not supportable.
- Generic entry risk is legally high but commercially constrained by small volume, sterile manufacturing, nephrotoxicity, and limited administration settings.
- The strongest potential value would come from a new formulation, localized delivery system, or validated indication with separate patent protection.
FAQs
Is cidofovir still FDA approved?
Vistide received FDA approval for CMV retinitis in adults with AIDS. The commercial availability of branded product can differ from the existence of the historical approval.
Is cidofovir available as a generic?
Cidofovir’s core patent protection has expired, but generic availability depends on jurisdiction, supplier economics, FDA applications, and sterile injectable manufacturing capacity.
Why is cidofovir rarely used for routine CMV treatment?
Its intravenous administration, nephrotoxicity, need for probenecid and hydration, and renal monitoring make it less convenient than valganciclovir or ganciclovir where those drugs remain effective.
Can cidofovir be used for adenovirus infection?
It is used off-label in selected immunocompromised patients with severe or refractory adenovirus infection. Evidence is more limited than for its original approved CMV indication.
Could brincidofovir replace cidofovir commercially?
Brincidofovir is a distinct lipid-conjugated antiviral and is not a generic substitute for cidofovir. Its approved smallpox indication does not establish it as a replacement for cidofovir in CMV or adenovirus treatment.
References
- U.S. Food and Drug Administration. (1996). Vistide (cidofovir injection) prescribing information. https://www.accessdata.fda.gov
- U.S. Patent and Trademark Office. (1992). U.S. Patent No. 5,142,051, antiviral phosphonate nucleotide analogs. https://patents.google.com/patent/US5142051
- Gilead Sciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://investors.gilead.com
- National Institutes of Health. (2024). Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. https://clinicalinfo.hiv.gov
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/‑fda‑drugsfda/index.cfm
